11-Apr-2023 By Ben Hargreaves
Cell Systems is a human primary cell and cell culture media company, with the deal allowing AnaBios to expand its existing portfolio.
04-Apr-2023 By Jonathan Smith
The Danish biotech Adcendo has bagged a Series A extension round of €31 million ($33.8 million), taking its Series A winnings so far to €82 million ($89.5 million). The round will bankroll the development of Adcendo’s pipeline of antibody-drug...
29-Mar-2022 By Rachel Arthur
While skills shortages present one of the main challenges to the biopharma industry, North Carolina believes its investments in the life science ecosystem have given it a ‘multiple decade jumpstart’ in building a successful biopharma hub for both manufacturing...
06-Jan-2022 By Rachel Arthur
Contract Research Organization (CRO) Texcell has held a breaking ground ceremony for a new facility in Frederick, MD.
04-Jun-2018 By Melissa Fassbender
Syngene International has inked a non-exclusive partnering agreement with the emerging immuno-oncology company Zumutor Biologics after collaborating for more than a year.
20-Feb-2018 By Flora Southey
Charles River says increased demand for biologics services prompted its recent Devon Park facility acquisition, bringing its Pennsylvania site count to three
17-Feb-2017 By Staff Reporter
Charles River Laboratories says it is positioning itself to take advantage of growing demand for biological services.
22-Nov-2016 By Gareth Macdonald
Cel-Sci has responded to the partial clinical hold imposed on a Phase III trial of its candidate head and neck cancer cell therapy Multikine in September.
04-Nov-2016 By Gareth Macdonald
Biologics manufacturing and testing activities helped Charles River Laboratories grow in Q3 and will drive further gains say analysts.
26-Oct-2016 By Gareth Macdonald
Cel-Sci has received written confirmation the US FDA has placed a late stage trial of its cancer cell therapy Multikine on partial clinical hold a month after agency first raised concerns.
21-Oct-2016 By Melissa Fassbender
PPD has added 4,300 square feet of new laboratory space for analytical testing of biopharmaceuticals and inhalation devices to the company’s Athlone, Ireland-based GMP facility.
29-Jun-2016 By Dan Stanton
Sartorius has expanded its bio-analytics capabilities through the $90m (€81m) acquisition of IntelliCyt.
12-Apr-2016 By Dan Stanton
Demand for biological products has driven recent investments in vaccine manufacturing and cell banking, says Charles River Laboratories.
07-Apr-2016 By Melissa Fassbender
The new collaboration aims to advance a workflow solution for biologics quantification.
21-Mar-2016 By Gareth Macdonald
BioPharmaSpec has set up business development teams for the Indian and Asia-Pacific markets and predicted increased demand for biosimilar characterisation services.
05-Nov-2015 By Fiona BARRY
Charles River has reported strong Q3 sales despite weakness in Japan and plans to grab space in emerging early discovery, bio-testing and Chinese markets.
17-Sep-2015 By Dan Stanton
China’s ShangPharma is building a $60m (€53m) single-use biologics manufacturing plant in Qidong, to be operated by its CMO subsidiary.
30-Jun-2015 By Gareth Macdonald
TxCell is set to expand a trial of its candidate Crohn’s disease cell therapy to the US after the FDA accepted its IND application.
03-Feb-2015 By Dan Stanton
The US FDA has reached out to industry for comments on the use of interchangeability data in the submission of biosimilars through the 351(k) pathway.
18-Nov-2014 By Gareth Macdonald
Collaboration does not mean drugmakers have started playing nice, it’s just that the pain of shared problems has become unbearable according to TransCelerate Biopharma CEO, Dalvir Gill.
17-Sep-2014 By Dan Stanton
Almost all of the biosimilars currently approved have been developed using a third-party research organisation according to a survey from the Association of Clinical Research Organizations (ACRO).
16-Sep-2014 By Fiona BARRY
Charles River Labs (CRL) has singled out China as an area of “disproportionate growth” in biologics R&D and says it is on the hunt for preclinical acquisitions in the region.
15-Nov-2013 By Dan Stanton
Biosimilar clinical trials are increasing but levels of physician oversight and regulatory decisions are still hurdles to overcome, say Parexel, PPD and Vince & Associates.
26-Feb-2013 By Zachary Brennan
Ireland-based CRO Icon unveiled higher than expected revenue and backlog increases in 2012 when compared to 2011, and the company expects even stronger results in 2013.
21-Feb-2013 By Dan Stanton
CiToxLAB says strong revenue growth in 2012 was due to a new global status following its acquisition of Lab Research.
07-Aug-2012 By Gareth Macdonald
Parexel may be willing to act as a matchmaker for the small and midsized developers that work with its new BioPharm unit according to COO Mark Goldberg.
23-Jul-2012 By Natalie Morrison
Outsourcing-Pharma.com presents its weekly low down of the movers and shakers in the world of pharmaceuticals, including news from Parexel, Ricerca, and CSC.
24-May-2012 By Gareth Macdonald
US CRO Pharmaceutical Product Development (PPD) predicts that new CEO Dave Simmons' ‘pharmaceutical industry experience’ gained at Pfizer will be an asset in guiding partnerships.
25-Jan-2012 By Nick Taylor
A patent loss-fuelled surge in big pharma outsourcing will push the European CMO market through the $20bn barrier by 2018, analysis claims.
CROs still seen as good investment says leading banker
22-Nov-2011 By Gareth Macdonald
The CRO industry is still considered a good long-term investment and the clinical services segment is set to continue its dominance thanks to sponsor R&D spending, says leading banker.
WuXi buys two Chinese CROs in clinical trial expansion
25-Oct-2011 By Nick Taylor
WuXi PharmaTech has expanded into Phase I-IV clinical trial services through the acquisition of two China-based CROs.
vivoPharm branch out in US with MPI partnership and new Hershey office
30-Aug-2011 By Natalie Morrison
vivoPharm has extended its oncology offering after striking up an alliance with MPI Research.
DavosPharma teams with Immunologix on 100% human MAbs for discovery
10-May-2011 By Gareth Macdonald
Chemistry services provider DavosPharma has added 100 per cent human antibodies to its discovery offering through a new alliance with Immunologix.
PPD expands consulting services into four new areas
10-May-2011 By Alexandria Pesic
North Carolina, US-based contract research organisation (CRO), PPD, has expanded its product development consulting services into four new areas.
Biobetters a big opportunity for biopharm and CROs
12-Apr-2011 By Nick Taylor
Biobetters, more than biosimilars, are the big opportunity for biopharm and CROs hoping to profit from biologics patent expirations, say experts.
Agilent buys Biocius Life Sciences for undisclosed amount
03-Mar-2011 By Alexandria Pesic
Agilent Technolgies, the Santa Clara, US-based scientific instrument manufacturer, has acquired instrument manufacturer and contract research organisation (CRO), Biocius Life Sciences, for an undisclosed amount.
Parexel sees Q2 revenue grow, but cuts 2011 outlook
01-Feb-2011 By Gareth Macdonald
US contract research organisation (CRO) Parexel has cut its 2011 guidance, citing slower backlog conversion from projects generated by “strategic partnerships” as basis for the revision.
Merck Millipore adopts Gyros’ early-stage assay tech
17-Nov-2010 By Wai Lang Chu
Merck Millipore says Gyros’ Gyrolab xP workstation will be a competitive advantage for its contract immunogenicity, pharmacokinetics and cGMP testing offering for the biopharmaceutical industry.
Latest deals and developments in the CRO space
11-Aug-2010 By Gareth Macdonald
Outsourcing-pharma presents a round-up of recent developments in the contract research sector, with news from Quintiles, Bioclinica and Cyprotex.
Lab Research lands 5 new “top 35” pharma clients
21-Jul-2010 By Gareth Macdonald
Preclinical CRO Lab Research says new contracts are a sign of continuing recovery in market as well as firm’s ability to attract broader clientele base.
Almac teams on X-ray data analysis; US plant nears completion
12-May-2010 By Staff Reporter
Almac hopes University College Cork solid state chemistry accord will bypass crystallisation hurdles and accelerate drug development.
GBI, Hyprocell collaborate to offer cell line development
29-Apr-2010 By Nick Taylor
CMO Goodwin Biotechnology Inc (GBI) is collaborating with Hyprocell to help clients that need manufacturing services but have a sub-optimal cell line producing low concentrations.
NexACT shows preclinical SR potential
18-Mar-2010 By Gareth Macdonald
CRO NexMed says new data from preclinical trials show that its NexACT delivery technology can act as a sustained release “depot” for drugs like insulin and taxol.
Parexel allies with Proteome to boost biomarker offering
15-Feb-2010 By Nick Taylor
Parexel has formed an alliance with Proteome Sciences to enhance its biomarker capabilities, allowing it to help clients make earlier assessments of new compounds in development.
MPI and Bioject form needle-free pact
06-Jan-2010 By Staff Reporter
US preclinical CRO MPI Research has formed an alliance with Oregon-based needle-free delivery specialist Bioject Medical Technologies.
Piramal expands contract services and research
08-Oct-2008 By Nick Taylor
India-based Piramal Healthcare has extended the range of early phase drug product development and manufacturing on offer at its Morpeth, UK facility.